Brain disorder management through Ayurveda on the basis of EEG

EEG Source Localization assisted Ayurvedic Intervention in Brain Disorder Management

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058237

Enrollment

Registered

2023-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G309- Alzheimers disease, unspecified Health Condition 2: G998- Other specified disorders of nervous system in diseases classified elsewhere

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: FOR VALIDATION OF EEG MACHINE: For Group I: Participant of either sex between the age group of 50-70 years on the basis of MMSE(Annexure 1) scale and routine pathological examination. For Group 2: 1. Newly Diagnosed case of MCI as per MMSE scale having score 20-23 a. between the age group of 50-70 years b. not taking any medication or taking medications = 3 weeks 2. Patients of Both the genders. TO EVALUATE THE EFFECT OF SARASWATA GHRITA Inclusion criteria 1. Patients between the age group of 50 to 70 years. 2. Patients of both genders. 3. Diagnosed case of MCI as per MMSE scale having score 20-23. 4. Diagnosed case of AD as per DSM IV (Annexure 2) criteria. 5. Patients of Both the genders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary outcome Clinical efficacy on the basis of ADAS scale for Alzheimer’s disease Secondary outcome Assessment on the basis of EEG data and quality of life of Alzheimer’s disease patients on QoL scale. Timepoint: Time point for primary outcome At 0th , 30th, 60th and 90th day Time point for secondary outcome For EEG data collection at 0th and 90th day For QoL at 0th, 30th, 60th and 90th day.	—

Measure

Time frame

Primary outcome Clinical efficacy on the basis of ADAS scale for Alzheimer’s disease Secondary outcome Assessment on the basis of EEG data and quality of life of Alzheimer’s disease patients on QoL scale. Timepoint: Time point for primary outcome At 0th , 30th, 60th and 90th day Time point for secondary outcome For EEG data collection at 0th and 90th day For QoL at 0th, 30th, 60th and 90th day.

—

Secondary

Measure	Time frame
Assessment of quality of life of Alzheimer’s disease patients on QoL scale. Timepoint: At 0th , 30th, 60th and 90th day.	—

Countries

India

Contacts

Public ContactDr Pramod R Yadav

ALL INDIA INSTITUTE OF AYURVEDA

drpramod88@gmail.com8930625596

Outcome results